While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses, struggling Allakos is welcoming a $0.33 per share buyout offer wi ...

Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to ...

Alumis (ALMS) and Acelyrin (SLRN) announced an amendment to the existing terms of their previously announced merger agreement: Acelyrin ...

Under the terms of the amended agreement, ACELYRIN stockholders will now receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, representing a meaningful ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major shark circling its waters. On Tuesday in a supplement to its annual ...

Keros Therapeutics said on Thursday its board had authorized a stockholder rights plan, also known as a "poison pill", in response to rapid accumulations of the company's stock by some investors.

St. Louis Post-Dispatch parent Lee Enterprises on Wednesday said its board has extended a "poison pill" shareholder rights plan amid takeover interest from the Hoffmann Family of Cos. St. Louis ...